CDC review finds that data for the benefit to patients of vaccinating health workers are limited.
Clinical trials will test a candidate vaccine for H7N9 flu in varying doses, some with immune boosters.
Over the 2 weeks that closed out August, flu activity in the world remained at low levels, with H3N2 as the predominant strain and 2009 pandemic H1N1 (pH1N1) and influenza B circulating in many countries as well, the World Health Organization (WHO) said today.
Scientists who conducted the first large-scale cholera outbreak control campaign in Africa using oral vaccine reported yesterday in PLoS One that immunization was well accepted by the public and that high vaccination coverage is possible, even in remote settings.
In a pair of puzzling statements, Saudi Arabia's Ministry of Health (MOH) on Sep 1 reported the recovery of four patients from Middle East respiratory syndrome coronavirus (MERS-CoV) infections, though two of them had previously been described as asymptomatic.
Findings raise concerns about an approach eyed for developing a "universal" flu vaccine.
GlaxoSmithKline (GSK) has won US Food and Drug Administration (FDA) approval of its second four-strain influenza vaccine, FluLaval Quadrivalent, making it the fourth such vaccine on the US market.
The number of Cyclospora cayetanensis infections across the country now stands at 576, an increase of 28 in the past 2 days, according to an update from the Centers for Disease Control and Prevention (CDC) this morning. The Texas Department of State Health Services (TDSHS) shows that state's number at 258, which is 18 more than the CDC's currentTexas count; with those included, the nationwide total would now be 594.
Comments from industry, public health, and providers on the debut of a new flu vaccine.
The percentage of healthcare workers who were vaccinated against flu during the most recent season appears to be about the same as for the 2011-12 season, according to interim numbers posted yesterday by the US Centers for Disease Control and Prevention (CDC).
